Positive Impact becomes exclusive distributor of Purifeyes
The optical supplier has signed an agreement with Clinical Health Technologies to distribute the Purifeyes spray
25 March 2021
Positive Impact has signed an agreement with Clinical Health Technologies (CHT) to become exclusive distributor for the Purifeyes spray in the independent optometry sector.
The ocular and periocular cleanser cares for the periocular skin, eyelids, eyelashes and eyebrows for normal and sensitive eyes, reducing microbial overgrowth, inflammation and long-term dry eye symptoms.
The solution cleanses, soothes and hydrates, and provides antimicrobial protection without the risk of microbial resistance.
The solution is recommended for the treatment, prevention and protection of eyelid margin inflammation, affecting glaucoma patients on long-term topical prostaglandin analogues, the company suggests, as well as 60% of contact lens wearers, and 85% of long-term visual display unit and digital device users.
The company suggests Purifeyes can be used before contact lens insertion and removal, before and after sports, before lash and brow treatments, as well as for daily hygiene. It can also be used whilst on public transport (such as in-flight), and for antimicrobial protection, as well as post periocular surgery aftercare.
The clinically-formulated solution can be sprayed directly onto the eye and surrounding area, or applied on a cotton pad or gauze. The company suggested that Purifieyes has the same PH as the ocular surface and is well tolerated by the mucous membranes of the conjunctiva.
Positive Impact’s marketing and professional services director, Nick Atkins, said: “I have long been aware of the antimicrobial benefits of hypochlorous acid for ocular and periocular hygiene. The challenge was finding the right product with the specific attributes of safety and efficacy we wanted. With its low concentration and high purity formulation, Purifeyes is that product.”
Purifeyes was co-developed by consultant ophthalmologists, Dr Jonathon Roos, a Cambridge PhD and former Harvard biology research fellow, and Dr Rachna Murthy, a consultant eye and plastic surgeon.